Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.44 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26008959 | 0.91 | MDM4 (0.50) | MDM4TP53MDM2SLC17A5CASP3 | |
| SCHEMBL9113360 | 0.89 | MDM4 (0.52) | MDM4TP53MDM2SLC17A5CASP3 | |
| SCHEMBL29160941 | 0.89 | MDM4 (0.48) | MDM4TP53MDM2SLC17A5CASP3 | |
| SCHEMBL29160943 | 0.89 | MDM4 (0.48) | MDM4TP53MDM2SLC17A5CASP3 | |
| SCHEMBL31370341 | 0.88 | MDM4 (0.51) | MDM4TP53MDM2SLC17A5CASP3 | |
| SCHEMBL849963 | 0.88 | MDM4 (0.51) | MDM4TP53MDM2SLC17A5 | |
| SCHEMBL32664869 | 0.87 | MDM4 (0.48) | MDM4TP53MDM2SLC17A5CASP3 | |
| SCHEMBL30002165 | 0.87 | MDM4 (0.48) | MDM4TP53MDM2SLC17A5CASP3 | |
| SCHEMBL16100700 | 0.87 | MDM4 (0.48) | MDM4TP53MDM2SLC17A5CASP3 | |
| SCHEMBL30959635 | 0.87 | MDM4 (0.48) | MDM4TP53MDM2SLC17A5CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203098-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE | JCR PHARMACEUTICALS CO., LTD. (JP) | 2023-06-29 | — | — | US | disclosed |
| EP-4108676-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE | JCR Pharmaceuticals Co., Ltd. (JP) | 2022-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203098-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE | TFRC, SLC3A2, SLC7A1 | MDM4 4269/4885TP53 2445/4885MDM2 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.